Imunon Q2 net loss widens slightly as R&D costs rise

Imunon

11/08/2026 13:09

Overview
US biotechnology firm's Q2 net loss widened slightly, driven by higher R&D expenses
Company reported strong enrollment progress in pivotal Phase 3 OVATION 3 trial for IMNN-001
Positive preliminary clinical data for IMNN-001 in ovarian cancer highlighted

Outlook
Imunon expects Phase 3 OVATION 3 trial enrollment to complete by first half of 2029
Company says OVATION 3 trial enrollment rate is exceeding internal forecasts

Result Drivers
R&D SPENDING - Higher research and development expenses linked to advancing the Phase 3 OVATION 3 trial for IMNN-001
TRIAL ENROLLMENT - Rapid enrollment and site activation in OVATION 3 trial exceeded company forecasts
CLINICAL DATA - Positive preliminary Phase 2 results showed deeper antitumor response and higher disease clearance rates for IMNN-001

Company press release: ID:nGNX2zDp1R

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
 
$0.54
 
Q2 Net Loss
 
$2.80 mln
 
Q2 Operating Expenses
 
$2.80 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Imunon Inc is $13.00, about 697.5% above its August 10 closing price of $1.63

Reuters Recommended Reads
Aug 11 - Shattuck Labs Q2 net loss widens as R&D spending rises
Aug 10 - Palisade Bio Q2 net loss widens on higher R&D costs
Aug 10 - Olema Pharmaceuticals Q2 net loss widens on higher clinical trial spending

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)